Newtown, Pa.-based Helius said each unit of the offering had a Class A share and a half-share warrant with an exercise price of roughly $1.17 (C$1.50). The company also said it got the go-ahead to list its share on the Toronto stock exchange under the “HSM” symbol, starting today.
“This is a very meaningful development for our company. We are proud to qualify for listing on the TSX and we are very excited to have the resources to continue to drive our business objectives,” president & CEO Phil Deschamps said in prepared remarks.
Helius said it plans to use the proceeds from the funding round to complete a clinical registry trial of its portable neuromodulation stimulator in treating traumatic brain injury, ahead of a bid for 510(k) clearance from the FDA. The cash will also go toward building commercial inventory and launched the device once it wins U.S. clearance. The company also plans to seek other indication for the device, including multiple sclerosis and stroke.
Mackie Research Capital was agent and sole bookrunner for the offering, receiving a cash commission of roughly $340,281 (C$436,050). Mackie also has an option on another 436,050 units at an exercise price of 78¢ (C$1.00), Helius said.
In January, the company drew down on the $5 million remaining in its credit facility from a Chinese investor and extended a research deal with the U.S. Army.
$1 = C$1.28173
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.